OrthoPediatrics Announces Distribution Agreement with OSSIO, Inc. to Provide Revolutionary Orthopedic Fixation Technology to U.S. Children’s Hospitals Nationwide
Rhea-AI Summary
OrthoPediatrics (Nasdaq: KIDS) announced an exclusive U.S. distribution agreement with OSSIO to supply OSSIOfiber bio-integrative, metal-free fixation implants to children’s hospitals nationwide.
The technology is designed for pediatric fractures and deformities, gradually integrating into bone within 18–24 months and aiming to reduce secondary hardware removal surgeries.
Positive
- Exclusive U.S. distribution rights for OSSIOfiber pediatric fixation implants
- Expansion of product portfolio in pediatric trauma and deformity care
- Technology designed to reduce secondary hardware removal surgeries
- Bio-integrative implants that fully integrate into bone within 18–24 months
Negative
- None.
News Market Reaction – KIDS
On the day this news was published, KIDS gained 4.16%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $20M to the company's valuation, bringing the market cap to $498.80M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 26 | Conference participation | Neutral | -2.0% | Participation in Goldman Sachs Global Healthcare Conference fireside chat. |
| Apr 30 | Earnings beat/guidance | Positive | +3.8% | Q1 2026 results with revenue growth and raised full‑year guidance. |
| Apr 30 | Product portfolio expansion | Positive | +3.8% | Launch of TRAXIO Complete Halo Gravity Traction system for pediatric spine. |
| Apr 16 | Earnings date notice | Neutral | +1.3% | Announcement of date and webcast details for Q1 2026 results. |
| Mar 31 | Conference participation | Neutral | +2.6% | Planned fireside chat at Needham Virtual Healthcare Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent KIDS news, especially earnings and product updates, has more often been followed by gains than declines.
Key Terms
bio-integrative medical
fixation technology medical
post-implantation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WARSAW, Ind., June 24, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced an exclusive distribution agreement with OSSIO, Inc. (“OSSIO”) that brings U.S. children’s hospitals nationwide a bio-integrative, metal-free fixation technology ideally suited for treatment of fractures and deformities in pediatric patients.
After performing their fixation function, OSSIOfiber® implants are gradually replaced by the patient’s newly formed bone during the natural healing process. This technological advance in material science decreases the need for hardware removal surgeries that pediatric patients who initially receive metal implants usually receive.
“Existing fixation technology requires pediatric orthopedic surgeons to consistently remove their patients’ metal implants in a second surgery that adds cost and risk,” said Joe Hauser, President of Trauma and Deformity at OrthoPediatrics. “OSSIOfiber implants reduce the rate of these secondary procedures by doing away with metal. From a strategic perspective, partnering with OSSIO expands our reach and capabilities with a revolutionary technology that complements OrthoPediatrics’ current product offering, allowing us to address more unmet pediatric needs while strengthening the company’s long-term growth potential.”
OSSIOfiber implants are made from a proprietary blend of natural mineral fibers that provide initial fixation strength comparable to traditional metal implants while safely and completely integrating into the patient’s own bone tissue within 18–24 months post-implantation, leaving no hardware behind.
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets nearly 90 systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 75 countries outside the United States. For more information, please visit www.orthopediatrics.com. For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit www.opsb.com.
Investor Contact
Philip Trip Taylor
Gilmartin Group
philip@gilmartinir.com
415-937-5406
